News
PTCT
24.69
-1.87%
-0.47
Weekly Report: what happened at PTCT last week (0408-0412)?
Weekly Report · 3d ago
PTC Therapeutics Price Target Maintained With a $45.00/Share by Cantor Fitzgerald
Dow Jones · 6d ago
Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $45 Price Target
Benzinga · 6d ago
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), KalVista Pharmaceuticals (KALV) and PTC Therapeutics (PTCT)
TipRanks · 04/11 10:00
Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)
TipRanks · 04/09 09:40
Shareholders in PTC Therapeutics (NASDAQ:PTCT) have lost 44%, as stock drops 5.5% this past week
PTC Therapeutics, Inc. Share price dropped 44% in the last year, despite the market returning 28%. The share price has dropped 13% in a month, and 43% over the last three years. The company's revenue grew by 34% in last year but shareholders have lost 44% over five years. It's important to look at the company's fundamentals before investing in the stock. PTC Therapedutics has 4 warning signs we think you should know about.
Simply Wall St · 04/08 11:32
Weekly Report: what happened at PTCT last week (0401-0405)?
Weekly Report · 04/08 09:02
Ptc Therapeutics: Statement of changes in beneficial ownership of securities
Press release · 04/04 21:26
PTC THERAPEUTICS INC <PTCT.O>: RBC RAISES TARGET PRICE TO $29 FROM $28
Reuters · 04/04 11:38
Solid Biosciences gets FDA rare pediatric disease status for DMD therapy
Healthcare Solid Biosciences gets FDA rare pediatric disease status for DMD therapy. SGT-003 for the treatment of Duchenne muscular dystrophy. The company expects the first patient in a Phase 1/2 study for the therapy to be dosed in Q2.
Seeking Alpha · 04/01 14:17
Weekly Report: what happened at PTCT last week (0325-0329)?
Weekly Report · 04/01 09:02
PTC Therapeutics Submits Sepiapterin MAA For Treatment Of PKU To EMA
Benzinga · 03/28 12:34
Weekly Report: what happened at PTCT last week (0318-0322)?
Weekly Report · 03/25 09:02
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
NASDAQ · 03/21 14:01
PTC Therapeutics Price Target Raised to $35.00/Share From $33.00 by Jefferies
Dow Jones · 03/21 12:26
PTC Therapeutics Is Maintained at Buy by Jefferies
Dow Jones · 03/21 12:26
PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
NASDAQ · 03/20 18:00
U.S. RESEARCH ROUNDUP-Dick's Sporting Goods, Nvidia, PVH
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Dick's Sporting Goods, Nvidia and PVH are among the companies. Hilton Worldwide Holdings and Cisco also raise their targets for the day. Some analysts raised their target prices for the companies on Wednesday.
Reuters · 03/20 07:14
PTC Therapeutics Gains After Announcement Of Key Regulatory Updates
NASDAQ · 03/19 16:19
Buy Rating for PTC Therapeutics Bolstered by Positive Regulatory Prospects and Gene Therapy Advances
TipRanks · 03/19 15:05
More
Webull provides a variety of real-time PTCT stock news. You can receive the latest news about Ptc Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).